Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 15.88 Mil Enterprise Value: 5.92 Mil PE Ratio: 0 PB Ratio: 0.92 GF Score: 52/100

Matinas BioPharma Holdings Inc At The Biotech Showcase Transcript

Jan 09, 2024 / 07:00PM GMT
Release Date Price: €8.7 (+5.45%)
Unidentified Participant

All right. We're going to start our next presentation by Matinas BioPharma from Bedminster, New Jersey, Matinas BioPharma is focused on hematology, infectious disease, and inflammation. Presenting for Matinas BioPharma is their CEO, Jerome Jabbour. Please go ahead.

Jerome Jabbour Matinas BioPharma Holdings Inc.;CEO

Thank you very much. It's great to be back at Biotech Showcase. It's always a great opportunity to kick off the year. And it's especially important for us because the fourth quarter for us, there was a lot of news. So it gives us an opportunity to sort of recap some of the data announcements we made, put them in context and then create expectations and milestones for what we hope to achieve in 2024.

I will be making forward-looking statements, so please, we would encourage you to check our SEC filings and be aware of all of the risks. Matinas is all about drug delivery. This is a platform drug delivery play with the technology that lends itself to intracellular delivery. But it takes things to the next level because it

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot